Novavax partners with contract drugmaker for COVID-19 vaccine manufacturing

An add-on component of Novavax's vaccine that could help enhance the immune response against the coronavirus would be manufactured by privately held AGC Biologics

  

Novavax Inc on Wednesday entered into a deal with contract drugmaker AGC Biologics to manufacture its experimental COVID-19 vaccine.

An add-on component of Novavax's vaccine that could help enhance the immune response against the coronavirus would be manufactured by privately held AGC Biologics, the contract drugmaker said. 

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Saumyadeb Chakrabarty) ((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 2676; Twitter: @SaumyaSibi;))

More From Health